The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
Open accessAbstract
Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal models of infections with other coronaviruses and for previous whole-cell inactivated vaccines developed for respiratory syncytial virus and measles virus, VAERD has usually been associated with the development of T helper 2 cell (TH2 cell)-biased CD4+ T cell responses, with significantly increased levels of interleukin-4 (IL-4), IL-5 and/or IL-13 (refs12,126,165–174).”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [171]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027
Self-citationSARS virus infection of cats and ferrets
Martina, B. E. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., Peiris, M. J. S., Lim, W. W. L., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/425915a · Cited by 571
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T., Lee, K.-C., Yao, H., Tsang, T. Y. O., Chow, T., Yeung, Y.-C., Choi, K., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 422
Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
Chakrabarti, S., Sisler, J. R., & Moss, B. A. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 391
Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications
Takada, A., & Kawaoka, Y. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.405 · Cited by 332
Collins, A. R., Knobler, R. L., Powell, H., & Buchmeier, M. J. (1982) · Virology · doi:10.1016/0042-6822(82)90095-2 · Cited by 317
Falkner, F. G., & Moss, B. A. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1849-1854.1988 · Cited by 317
Antibody-Dependent Enhancement of Virus Infection and Disease
Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316
Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276
Weiss, R. C., & Scott, F. W. (1981) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/0147-9571(81)90003-5 · Cited by 242
Fleming, J. O., Stohlman, S. A., Harmon, R. C., Lai, M. M. C., Frelinger, J. A., & Weiner, L. P. (1983) · Virology · doi:10.1016/0042-6822(83)90498-1 · Cited by 163
Olsen, C. W. (1993) · Veterinary Microbiology · doi:10.1016/0378-1135(93)90126-r · Cited by 119
Susceptibility of Pigs and Chickens to SARS Coronavirus
Weingartl, H. M., Copps, J. S., DREBOT, M. A., Marszal, P., Smith, G. A., Gren, J., Andonova, M., Pasick, J. M. M., Kitching, P., & Czub, M. (2004) · Emerging infectious diseases · doi:10.3201/eid1002.030677 · Cited by 85
Self-citationComparison of assays for the detection of West Nile virus antibodies in chicken serum.
Weingartl, H. M., DREBOT, M. A., Hubálek, Z., Halouzka, J., Andonova, M., Dibernardo, A., Cottam-Birt, C., Larence, J. E., & Marszal, P. (2003) · Europe PMC (PubMed Central) · Cited by 58
Self-citationAdverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
Glansbeek, H. L., Haagmans, B. L., Lintelo, E. G. T., Egberink, H. F., Duquesne, V., Aubert, A., Horzinek, M. C., & Rottier, P. J. M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-1-1 · Cited by 50
Virology: SARS virus infection of cats and ferrets
Bartlett, J. G. (2004) · Infectious Diseases in Clinical Practice · Cited by 34
Cited by
Sorted by citations
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Coronaviruses — drug discovery and therapeutic options
Zumla, A. I., Chan, J. F., Azhar, E. I., Hui, D. S. C., & Yuen, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,711
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292
Metadata
- Authors
- CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J.
- Affiliations
- Canadian Science Centre for Human and Animal Health (CA)
- University of Manitoba (CA)
- Corresponding author
- CAO, J
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2005-03-18
- Volume
- 23
- Issue
- 17-18
- Pages
- 2273-2279
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC7115540
- OpenAlex
- W2169462787
- Cited by
- 180
- References
- 17
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 9 · 2022: 14 · 2021: 36 · 2020: 55 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Vaccine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Food Inspection Agency
- Health Canada
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Keywords
- SARS-CoV, modified vaccinia Ankara, recombinant vaccine, spike protein, nucleocapsid protein, ferrets, vaccine efficacy, vaccine safety, liver necrosis, inflammation
- MeSH terms
- Coronavirus Nucleocapsid Proteins, Animals, Antigens, Viral, Base Sequence, DNA, Viral, Ferrets, Hepatitis, Viral, Animal, Male, Membrane Glycoproteins, RNA, Viral, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines, Nucleocapsid Proteins, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
